Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

GILEAD SCIENCES : Ex-dividend day for

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/13/2019 EDT

A dividend is removed today from Gilead Sciences's share.



© Factset 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
09:10aGILEAD SCIENCES : Chief Scientific Officer John McHutchison to Leave
DJ
08:36aGILEAD SCIENCES INC : Change in Directors or Principal Officers, Financial State..
AQ
08:32aGILEAD SCIENCES : Announces Changes to Senior Leadership Team
BU
08:31aGILEAD SCIENCES : rsquo; Chief Scientific Officer John McHutchison to Leave the ..
BU
07/16GILEAD SCIENCES : to Release Second Quarter 2019 Financial Results on Tuesday, J..
BU
07/16GSK's two-drug HIV Dovato treatment meets main goal in study
RE
07/16GILEAD SCIENCES : Kite Announces Plans to Bolster Industry-Leading Cell Therapy ..
BU
07/15S&P ends near flat as Citigroup results sink banks; Nasdaq hits new high
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
More news
Financials (USD)
Sales 2019 22 020 M
EBIT 2019 11 469 M
Net income 2019 7 013 M
Debt 2019 2 514 M
Yield 2019 3,76%
P/E ratio 2019 12,2x
P/E ratio 2020 12,1x
EV / Sales2019 3,98x
EV / Sales2020 3,64x
Capitalization 85 118 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 80,65  $
Last Close Price 66,94  $
Spread / Highest target 41,9%
Spread / Average Target 20,5%
Spread / Lowest Target -11,9%
EPS Revisions
Managers
NameTitle
Gregg H. Alton Chief Executive & Patient Officer
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES7.02%84 164
VERTEX PHARMACEUTICALS6.43%45 080
REGENERON PHARMACEUTICALS-20.12%31 857
SAREPTA THERAPEUTICS INC40.43%11 437
GENMAB14.24%11 148
ARRAY BIOPHARMA INC225.40%10 445